- About Us
- Nano-Social Network
- Nano Consulting
- My Account
RUSNANO CEO Anatoly Chubais and MP Biomedicals CEO Milan Panic have signed an agreement of cooperation. The parties have agreed to cooperate in organization of nanotechnology research and development, in creation and modernization of R&D base, and in providing due conditions for production of innovative pharmaceuticals, including personal pharmacogenetic treatments.
RUSNANO and MP Biomedicals plan to jointly implement projects aimed at the increase in life expectancy and anti-aging as well as creating infrastructure for innovations in the area of nanobiotechnology.
The parties have agreed to participate in the work of scientific, coordinating and other councils, expert commissions and working groups on nanobiotechnology and pharmaceutical industry, that relate to areas of the signed agreement. RUSNANO and MP Biomedicals also decide to jointly provide mutual methodological and scientific-medical support for studies of the nanotechnology.
RUSNANO and MP Biomedicals will also collaborate in creating the information infrastructure to ensure the establishment and support of databases on scientific and medical developments and innovative projects in the field of biotechnology, pharmaceutical industry and nanotechnology.
The parties will elaborate the long-term forecast for areas of nanotechnology application in the field of life sciences, pharmaceutics and related industries with the allocation of promising emerging markets, products and services, as well as a list of priorities and critical technologies in the pharmaceutical industry. In addition, RUSNANO and MP Biomedicals will consider investments in the regions with already developed pharmaceutical industry.
The Russian Corporation of Nanotechnologies (RUSNANO) was established in 2007 by the Federal law ¹ 139-FZ to enable Government policy in the field of Nanotechnology.
To accomplish this task, RUSNANO co-invests in nanotechnology industry projects that have high commercial potential or social benefit. Early-stage investment by RUSNANO lowers the risk of its investment partners from the private sector.
RUSNANO participates in building nanotechnology infrastructure, which includes the nanotechnology centers of excellence, business incubators and early stage investment funds. RUSNANO provides scientific and educational programs that are required for its investment projects to succeed, and also supports the popularization of nanoscience and nanotechnology. RUSNANO selects promising spheres for investment based on longer-term sight created by the leading Russian and world experts.
To assist the Russian nanotechnology industry advance to the global market and strengthening of its international links RUSNANO develops partnerships with the leading nanotechnology centers in the world and organizes the annual Nanotechnology International Forum in Russia.
About MP Biomedicals
MP Biomedicals (known as ICN Biomedicals until 2003) manufactures and sells more than 55,000 products and is one of the only companies in the industry to offer a comprehensive line of life science, fine chemical and diagnostic products.
MP Biomedicals is a world-wide corporation, with ISO-certified and FDA-approved manufacturing and distribution facilities throughout the globe and headquartered in Southern California. A vast network of global distributors and satellite facilities and offices throughout Europe, Asia, Australia and the Americas assures customers top quality products delivered when and where needed.
MP Biomedicals is founded in 1959, it is headquartered in Santa Ana, California (USA). The founder and CEO of MP Biomedicals is Milan Panic, the American businessman of Serbian origin ,former prime minister and defense minister of Yugoslavia (1992 1993).
For more information, please click here
Anna Fradkova, press-secretary of the international press office
P.: +7 495 5424444 add.1424
M.: +7 985 7299860
Copyright © RUSNANOIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanotubes that build themselves April 14th, 2017
Nanotubes that build themselves April 14th, 2017
Leti Announces EU/South Korean Project for World’s First 5G-system Prototype: Coinciding with the 2018 Winter Games in PyeongChang, Korea, Prototype Will Be First Time State-of-the-art Terrestrial Wireless Communication Is Seamlessly Combined with Disruptive Satellite Communicati April 4th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017
Better living through pressure: Functional nanomaterials made easy April 19th, 2017
Shedding light on the absorption of light by titanium dioxide April 14th, 2017